Abstract Increasing evidence suggests that thiazolidinediones (TZDs) could have a therapeutic potential for patients with cancers. Here, the evidence on the mechanisms by which TZDs could contribute to different steps of cancer biology in the digestive system is summarized. According to studies, TZDs induce anti-cancer actions through 3 main pathways: (1) cell growth arrest, (2) induction of apoptosis, and (3) inhibition of cell invasion. Cell growth arrest is induced by an increased level of p27 Kip1 . p27
Introduction
Thiazolidinediones (TZDs), including rosiglitazone, pioglitazone, troglitazone, and ciglitazone, are high-affinity ligands for the peroxisome proliferator-activated receptor c (PPARc) [1] , a transcription factor preferentially expressed in adipose tissue [2] . These TZDs improve insulin sensitivity by regulating many aspects of adipose tissue function through the transcriptional activation of certain insulinsensitive genes involved in glucose homeostasis, fatty acid metabolism, and triacylglycerol storage in adipocytes [3, 4] . In addition to adipose tissue, many human cancer cell lines have been reported to exhibit high levels of PPARc expression. Exposure of these tumor cells to TZDs, especially troglitazone and ciglitazone, led to cell growth inhibition [5, 6] , suggesting anti-tumor activities of TZDs.
In addition to basic research evidence that TZDs produce anti-tumor effects on several cultured cancer cells [5, 6] , Govindarajan et al. [7] recently reported a retrospective analysis of a database from 10 Veteran Affairs medical centers in the USA which was conducted to assess the influence of TZDs used to treat diabetes mellitus. The clinical study observed a 33% reduction in lung cancer risk among TZD users compared with nonusers after adjusting for confounder interactions, suggesting that TZD use was associated with reduced risk of lung cancer. Thus, TZD clinically used is capable of preventing the development of cancers. Based on this evidence, it would be considered that TZDs have a therapeutic potential for patients with cancers.
In this review, the molecular mechanisms by which TZDs could exert anti-tumor actions in cancers in the digestive system are summarized. Studies suggest that 3 major pathways are deeply implicated in the TZD-induced anti-cancer effects: (1) cell growth arrest, (2) induction of apoptosis, and (3) inhibition of cell invasion, as shown in Fig. 1 .
Cell growth arrest by TZDs
Studies have shown that TZDs inhibit cell cycle progression at the G1/S checkpoint in cancer cells [5, 6] . So far, it has been reported increase levels of cell cycle arrest-related molecules, and decreased levels of cell cycle promotionrelated molecules, would be involved in the TZD-induced growth arrest in cancer cells as shown in Fig. 1 . Among them, p27
Kip1 , a cyclin-dependent kinase inhibitor, may be a key molecule that is implicated in the cell growth arrest induced by TZDs in human cancer cells in that TZDs increased the level of p27
Kip1 protein and the inhibition of cell proliferation by troglitazone was not observed in cells transfected with an antisense oligonucleotide against p27
Kip1 in human pancreatic cancer cells [8] . In addition, cell growth arrest accompanied with p27
Kip1 accumulation was also observed in gastric cancer [9] and hepatocellular carcinoma [10, 11] which had been treated with TZDs, suggesting that the increased level of p27
Kip1 protein may be a common mechanism by which TZDs induce the inhibition of cell growth in a wide variety of cancer cells. Since p27 Kip1 mRNA was unaltered by TZD [11] , it has been suggested that posttranslational mechanisms should have been involved in the p27
Kip1 accumulation caused by TZD. A ubiquitin-proteasome pathway is implicated in the posttranslational mechanisms of p27
Kip1 regulation [12] [13] [14] . The two major systems for degradation of p27 Kip1 protein-proteasome activity and function of skp2, a key enzyme for p27
Kip1 ubiquitylation as a ubiquitin ligasewere inhibited by TZDs in human gastric cancer cells and hepatocellular carcinoma cells [9, 10, 15] . Since a proteasome inhibitor, lactacystin, inhibited proteasome activity, and increased the protein level of p27
Kip1 as well as TZD does [9] , this suggested that TZD inhibits proteasome activity leading to accumulation of p27 Kip1 protein. These results suggest that the TZD-induced growth inhibition was mediated by p27
Kip1 accumulation which is induced by both inhibition of ubiquitylation of p27
Kip1 by down-regulation
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Anti-tumor effects WAF1/Cip1 or p27 Kip1 , and/or decreased levels of cell cycle promotion-related molecules such as cyclin D1, cyclin B1, cyclin E, CDK2, or CDK4. p27
Kip1 accumulation is induced by the inhibition of the ubiquitin-proteasome system (decreased expression of skp 2, an enzyme for p27
Kip1 ubiquitylation as a ubiquitin ligase, and inhibition of proteasome activity that degrades p27 Kip1 protein) and/or inhibition of MEK-ERK signaling. TZDs induce apoptosis through increased levels of apoptotic molecules such as p53, PTEN, or bax, and/or decreased level of anti-apoptotic molecules such as bcl-2/bcl-xL or survivin. Inhibition of cell invasion is induced by TZDs through up-regulation of E-cadherin and claudin-4 and/or down-regulation of MMP-2, MMP-9, or PAI-1. Inhibition of MEK-ERK signaling by TZDs may be involved in the increased expression of E-cadherin and claudin-4 of skp2 expression and reduction of degradation activity of p27
Kip1 by proteasome as shown in Fig. 1 . In addition to p27 Kip1 , several molecules related to cell cycle progression [16] have been listed as potential mediators that are involved in cell growth arrest by TZDs. As illustrated in Fig. 1 , these include up-regulation of p21 WAF1/Cip1 [11] and down-regulation of cyclin D1, cyclin B1, cyclin E, CDK2, or CDK4 [17] [18] [19] [20] .
A role of mitogen-activated protein kinases (MAPKs), extracellular signal related kinase (ERK), c-Jun N-terminal protein kinase (JNK), and p38 MAPK was examined in TZD-induced inhibition of cell growth in human pancreatic cancer cells [21] . Among the three kinases, troglitazone specifically inhibited the phosphorylation of ERK1/2 in a dose-and time-dependent manner. Troglitazone also downregulated the protein expression of mitogen-activated protein kinase kinase (MEK)1/2, an upstream molecule that regulates ERK phosphorylation. Treatment of human pancreatic cancer cells with a specific MEK inhibitor, PD98059 or U0126, inhibited ERK1/2 phosphorylation and cell growth. In addition, MEK inhibitors could increase expression of p27 Kip1 , suggesting that the inhibition of the MEK1/2-ERK1/2 signaling pathway may be implicated in the growth inhibitory effect through accumulation of p27
Kip1 protein in human pancreatic cancer cells. As described below, it is of interest that the inhibition of the MEK1/2-ERK1/2 signaling pathway may also contribute to the inhibition of cell invasion by TZDs (Fig. 1) .
Apoptosis induced by TZDs
TZDs also induce apoptosis in a variety of cells [22] [23] [24] [25] . With regard to the mechanism by which TZDs induce apoptosis, p53 might be involved in the induction of apoptosis in gastric cancer cells as follows. TZD-induced apoptosis in cultured human gastric cancer cells, MKN-28, MKN-45, and MKN-74 but not in KATO-III [26] . It has been demonstrated that p53, an apoptosis-inducible gene, is deleted only in KATO-III, whereas mutated or wild-type p53 is in MKN-28, MKN-45, or MKN-74, suggesting a possibility that p53 may mediate the apoptotic induction in human gastric cancer cells. BADGE, a synthetic PPARc antagonist [27] , significantly blocked the TZDs-induced apoptosis in gastric cancer cells, suggesting that troglitazone-evoked gastric cancer cell apoptosis is mediated by PPARc activation. In the dominant-negative p53 mutant cells, troglitazone failed to induce apoptosis, strongly indicating that p53 indeed mediates the process of the troglitazone-induced apoptosis. In addition to p53, TZDs inhibit the anti-apoptotic functions of Bcl-xL and Bcl-2 [28, 29] and stimulate apoptotic functions of bax and PTEN, leading to apoptosis [30] [31] [32] .
Survivin is the smallest member of the inhibitor of apoptosis gene family in mammalian cells [33] . High expression of survivin was associated with decreased survival in certain cancers [34] . A couple of reports have demonstrated that TZDs inhibited expression of survivin in a variety of cancer cells [35, 36] . TZD inhibits expression of survivin, thereby reducing anti-apoptotic action; in other words, inducing apoptosis. In summary, TZDs induce apoptosis not only through increased levels of apoptotic factors such as p53, PTEN, or bax, but decreased levels of anti-apoptotic factors such as Bcl-2/Bcl-xL or survivin (Fig. 1) .
In addition to the above molecular mechanisms of the induction of apoptosis by TZDs, mtDNA damage by troglitazone should be mentioned as a prime initiator of the hepatoxicity caused by this drug. Among TZDs, only troglitazone was removed from the market in 2000 because of hepatoxicity [37] . A number of hypotheses have been proposed to explain the troglitazone-induced hepatoxicity. These include the formation and accumulation of toxic metabolites, mitochondrial dysfunction and oxidant stress, inhibition of the bile salt transporter and bile acid toxicity, and the induction of apoptosis [37] . Rachek et al. [38] recently examined the effects of troglitazone or rosiglitazone on the primary human hepatocytes. According to their report, troglitazone induced apoptosis and significant mtDNA damage by troglitazone is considered to be a prime initiator of the hepatoxicity caused by this drug. The PPARc antagonist GW9662 did not block the troglitazoneinduced decrease in cell viability, indicating that the hepatotoxicity is PPARc-independent. Since rosiglitazone at equimolar concentrations failed to induce the change observed by using troglitazone, this suggested that hepatoxicity occurred in a troglitazone-specific manner. This evidence may lead us to speculate that mtDNA damage may contribute to the pharmacological actions such as apoptosis especially in cells with troglitazone.
Inhibition of cell invasion by TZDs
Increasing evidence has indicated that TZDs inhibit cell invasion and metastasis in various kinds of human cancer cells. Various molecular mechanisms by which TZDs inhibit cancer cell invasion have been reported. In general, matrix metalloproteinases (MMPs) or plasminogen activator inhibitor-1 (PAI-1) play a vital role in cancer cell invasion and metastasis [39, 40] . Sawai et al. [41] demonstrated that TZD inhibited pancreatic cancer cell invasion, which was largely mediated by modulation of the plasminogen activator system. Galli et al. [42] showed that TZD inhibited pancreatic cancer cells invasiveness, involving MMP-2 and PAI-1 expression. According to the report by Liu et al. [43] , down-regulation of MMP-9 as well as MMP-2 by TZDs would be implicated in the inhibition of cell invasion. Thus reports have suggested that the plasminogen activator system and MMPs may play a role in the TZDs-induced suppression of cell invasiveness.
Epithelial-mesenchymal transition (EMT) is implicated in the progression of cancer cells [44] . E-cadherin is a key player in EMT in cancer cell progression. Recent observation has indicated that TZD increased expression of E-cadherin, suggesting that TZD up-regulates E-cadherin expression, thereby reducing cell invasive activity in human pancreatic cancer cells [45, 46] . The tight junction proteins claudins are abnormally regulated in several human cancers. Although the exact roles of claudins in tumorigenesis are still being uncovered, it is clear that they represent promising targets for cancer detection, diagnosis, and therapy [47] . For example, Michl et al. [48] demonstrated that claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Recent evidence has suggested TZD increased expression of claudin-4 in human pancreatic cancer cells [46] , suggesting that claudins expression could be changed by TZDs. It was furthermore suggested that the increased expression of claudin-4 might play a role in the TZD-induced inhibition of cell invasion in cancer cells because claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer [48] . A MEK inhibitor, U0126, increased E-cadherin or claudin-4 mRNA and protein expression, and potently inhibited cell invasion [46] . Because TZD downregulates MEK-ERK signaling and inhibit cell invasion in human pancreatic cancer cells [21] , TZD increases expression of E-cadherin and claudin-4 possibly through inhibition of MEK-ERK signaling in pancreatic cancer cells, which might be involved in the TZD-induced inhibition of cell invasive activity (Fig. 1) .
PPARc-independent effects induced by TZDs
In addition to PPARc-dependent actions, TZDs induce a number of PPARc-independent effects [28, 49, 50] . For example, TZDs have been shown to stimulate the proteosomal degradation of cyclins D1 and D3 [51, 52] to block the cell cycle progression, and to scavenge toxic reactive oxygen species (ROS) [53] through PPARc-independent mechanisms. In addition, up-regulation of PTEN/ AMPK and down-regulation of Akt/mTOR/p70S6 signaling cascades are involved in the anti-tumor effects exerted by TZDs in a PPARc-independent manner [50] . From a different point of view, a PPARc-independent mechanism should be considered in cancer cells treated with TZDs, as follows. LNCaP prostate cancer and MCF-7 breast cancer cells, both of which exhibit low PPARc expression levels, were more sensitive to the effects of TZDs such as troglitazone and ciglitazone on suppressing cell viability than their PPARc-overexpressing counterparts, PC-3 and MDA-MB-231 cells, respectively [28, 51] . Based on these PPARc-independent actions of TZDs, we should consider that both PPARc-dependent and -independent pathways may contribute to the anti-cancer action exerted by TZDs.
Conclusion
Investigation into molecular mechanisms that underlie TZD-induced anti-cancer effects constitutes an area of active research. Cell growth arrest, induction of apoptosis, and inhibition of cell invasion seem to be deeply involved in the anti-cancer effects produced by TZDs. We do not know at this moment whether there are any other key molecules, other than those listed in this review, involved in the anti-cancer effects exerted by TZDs. Further studies should provide a better picture of all molecular mechanisms by which TZDs induce anti-cancer actions. An entire understanding of the molecular network related to the anti-cancer actions induced by TZDs could contribute to the development of treatments strategies with new perspectives.
